Get the Stockscreener App
14.91
0.30%
-0.015
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $14.91, with a volume of 1.07M.
It is down -0.30% in the last 24 hours and up +8.81% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$14.93
Open:
$14.93
24h Volume:
1.07M
Relative Volume:
0.12
Market Cap:
$17.20B
Revenue:
$14.33B
Net Income/Loss:
$-3.79B
P/E Ratio:
-4.705
EPS:
-3.17
Net Cash Flow:
$1.84B
1W Performance:
-6.68%
1M Performance:
+8.81%
6M Performance:
+40.96%
1Y Performance:
+61.27%
1-Day Range:
$14.82
$15.01
1-Week Range:
$14.82
$16.47
52-Week Range:
$6.85
$16.47
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
14.94 | 17.20B | 14.33B | -3.79B | 1.84B | -3.17 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.46 | 59.23B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
129.19 | 55.34B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.90 | 49.30B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.97 | 39.43B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
523.97 | 21.70B | 3.13B | 1.27B | 1.12B | 26.39 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Upgrade | UBS | Neutral → Buy |
| Jan-16-26 | Upgrade | Argus | Hold → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-15-25 | Initiated | Truist | Buy |
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Viatris Earnings Call Highlights Slow Growth, Cash Strength - TipRanks
UBS Raises Viatris (VTRS) Price Target as Cost Savings and Growth Outlook Improve - Insider Monkey
VTRS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
UBS raises Viatris stock price target to $20 on cost savings - Investing.com India
Rx Rundown: Gilead Sciences, Viatris, Generate Biomedicines and moreMM+MMedical Marketing and Media - Medical Marketing and Media
UBS Adjusts Viatris Price Target to $20 From $18, Maintains Buy Rating - marketscreener.com
Viatris Inc. (NASDAQ:VTRS) Q4 2025 Earnings Call Transcript - Insider Monkey
Viatris Inc. (VTRS) FDA Accepts sNDA for Presbyopia Treatment with October PDUFA Date - Yahoo Finance UK
JPMorgan Adjusts Price Target on Viatris to $17 From $16, Maintains Neutral Rating - marketscreener.com
Decoding Viatris Inc (VTRS): A Strategic SWOT Insight - GuruFocus
BofA raises Viatris stock price target on cost-cutting plan - Investing.com
Is Strong Q4 Revenue And Steady Dividend Policy Altering The Investment Case For Viatris (VTRS)? - simplywall.st
Viatris Looks Well-Positioned for Durable Growth From New Launches and Cost Savings Initiatives - Morningstar
Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up - Yahoo Finance
Earnings call transcript: Viatris Q4 2025 earnings beat forecasts, stock up - Investing.com
Viatris Q4 2025 slides: earnings beat, major cost-cutting plan By Investing.com - Investing.com South Africa
Restructuring: Viatris to cut global workforce by about 10% - Pittsburgh Post-Gazette
Viatris Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy - FinancialContent
Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Viatris (VTRS) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
Viatris Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Viatris Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:VTRS) 2026-02-26 - Seeking Alpha
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q4 CY2025 - Finviz
Viatris forecasts 2026 profit below estimates on India manufacturing woes - marketscreener.com
Viatris Launches Major Restructuring After Strong 2025 Results - TipRanks
Viatris maintains annual dividend at 48 cents for 2026 - Investing.com
Viatris shares fall on lower-than-expected 2026 profit outlook - Investing.com Australia
Viatris Posts Narrower Loss In Q4; Expects Workforce Reduction Of Up To Approx. 10% - Nasdaq
Viatris Q4 25 Earnings Conference Call At 8:30 AM ET - Nasdaq
Viatris beats on Q4; eyes 10% staff reduction (VTRS:NASDAQ) - Seeking Alpha
Viatris : VTRS Q4 2025 Non GAAP Reconciliations FINAL - marketscreener.com
Viatris : VTRS Q4 2025 Earnings Infographic - marketscreener.com
Viatris: Q4 Earnings Snapshot - marketscreener.com
Viatris beats estimates, stock edges up By Investing.com - Investing.com UK
Insights into Viatris Q4 Earnings - Benzinga
Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results - PR Newswire
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend - ChartMill
Viatris Inc. Stock Nears 52-Week High Ahead of Q4 Earnings: Shares Climb on Pipeline Strength - International Business Times Australia
Global healthcare company Viatris Inc. recently disclosed that its pharmaceutical manufacturing facility in Nashik, India, has currently suspended production activities due to a fire incident that occurred in February this year. - Bitget
Key facts: FDA Accepts Viatris' MR-141 Application; Q4 Results Due Soon - TradingView
Investors await Viatris earnings amid cost-cutting optimism By Investing.com - Investing.com Nigeria
Viatris Q4 2025 Earnings Preview: Revenue Forecast & Analyst ExpectationsNews and Statistics - IndexBox
Analysts optimistic ahead of Viatris' Q4 earnings driven by healthy drugs pipeline - Seeking Alpha
FDA accepts Viatris presbyopia treatment application - Investing.com
Viatris, Opus gain as FDA to review label expansion for eyecare drug - Seeking Alpha
FDA Accepts Viatris Inc. Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - marketscreener.com
FDA accepts Viatris supplemental new drug application for Mr-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia - marketscreener.com
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia - The AI Journal
FDA Accepts Viatris Supplemental New Drug Application For Mr-141 (Phentolamine Ophthalmic Solution 0.75%) For The Treatment Of Presbyopia - TradingView
Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow - Yahoo Finance UK
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
1.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):